The level of activated NK (CD49b+NKp46+; CD49b+CD69+) cells was significantly increased following combination therapy in breast tumors, while in melanoma tumors their level was elevated both following cGAMP administration and in its combination with RGD-(KLAKLAK)2. This evidence concerns the gene NCR1 and melanoma.